em. prof. dr. Geert Leroux-Roels

Journal Article
open access

Safety and Immunogenicity of a Carbohydrate Fatty Acid Monosulphate Ester Adjuvant Combined with a Low-Dose Quadrivalent Split-Virion Inactivated Influenza Vaccine: A Randomised, Observer-Blind, Active-Controlled, First-in-Human, Phase 1 Study

Valentino D'Onofrio (UGent) , Sharon Porrez (UGent) , Bart Jacobs (UGent) , Azhar Alhatemi (UGent) , Fien De Boever (UGent) , Gwenn Waerlop (UGent) , Els Michels, Francesca Vanni, Alessandro Manenti, Geert Leroux-Roels (UGent) , et al.

(2024) Vaccines. 12(9).

Add to list

Journal Article

Safety and immunogenicity of the live-attenuated hRVFV-4s vaccine against Rift Valley fever in healthy adults: a dose-escalation, placebo-controlled, first-in-human, phase 1 randomised clinical trial

Isabel Leroux-Roels (UGent) , Chittappen Kandiyil Prajeeth, Amare Aregay, Niranjana Nair, Guus F Rimmelzwaan, Albert D M E Osterhaus, Simone Kardinahl, Sabrina Pelz, Stephan Bauer, Valentino D'Onofrio (UGent) , et al.

(2024) The Lancet Infectious Diseases.

Add to list

Journal Article

Safety and Immunogenicity of a Carbohydrate Fatty Acid Monosulphate Ester Adjuvant Combined with a Low-Dose Quadrivalent Split-Virion Inactivated Influenza Vaccine: A Randomised, Observer-Blind, Active-Controlled, First-in-Human, Phase 1 Study

Valentino D’Onofrio, Sharon Porrez (UGent) , Bart Jacobs, Azhar Alhatemi, Fien De Boever, Gwenn Waerlop (UGent) , Els Michels, Francesca Vanni, Alessandro Manenti, Geert Leroux-Roels (UGent) , et al.

(2024) Vaccines. 12(9).

Add to list

Journal Article
A1
open access

Immune responses in healthy adults elicited by a bivalent norovirus vaccine candidate composed of GI.4 and GII.4 VLPs without adjuvant

Gwenn Waerlop (UGent) , Yorick Janssens (UGent) , Bart Jacobs (UGent) , Franziska Jarczowski, André Diessner, Geert Leroux-Roels (UGent) , Victor Klimyuk, Isabel Leroux-Roels (UGent) and Frank Thieme

(2023) FRONTIERS IN IMMUNOLOGY. 14.

Add to list

Journal Article
A1
open access

Immunogenicity, safety, and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate : a randomised, double-blind, placebo-controlled, phase 2a trial

Isabel Leroux-Roels (UGent) , Paul Willems, Gwenn Waerlop (UGent) , Yorick Janssens (UGent) , Jessika Tourneur, Fien De Boever (UGent) , Jacques Bruhwyler, Azhar Alhatemi (UGent) , Bart Jacobs (UGent) , Florence Nicolas, et al.

(2023) LANCET INFECTIOUS DISEASES. 23(12). p.1360-1369

Add to list

Journal Article
A1
open access

Human immunity and susceptibility to influenza A(H3) viruses of avian, equine, and swine origin

Elien Vandoorn, Wojciech Stadejek (UGent) , Isabel Leroux-Roels (UGent) , Geert Leroux-Roels (UGent) , Anna Parys (UGent) and Kristien Van Reeth (UGent)

(2023) EMERGING INFECTIOUS DISEASES. 29(1). p.98-109

Add to list

Journal Article
A1
open access

Double-blind, placebo-controlled, dose-escalating study evaluating the safety and immunogenicity of an epitope-specific chemically defined nanoparticle RSV vaccine

Isabel Leroux-Roels (UGent) , Jacques Bruhwyler, Lilli Stergiou, Mark Sumeray, Jasper Joye, Cathy Maes, Paul-Henri Lambert and Geert Leroux-Roels (UGent)

(2023) VACCINES. 11(2).

Add to list

Journal Article
A1
open access

A human monoclonal antibody against HBsAg for the prevention and treatment of chronic HBV and HDV infection

Rani Burm (UGent) , Freya Van Houtte (UGent) , Lieven Verhoye (UGent) , Ahmed Atef Ahmed Abouzeid Mesalam (UGent) , S Ciesek, P Roingeard, H Wedemeyer, Geert Leroux-Roels (UGent) and Philip Meuleman (UGent)

(2023) JHEP REPORTS. 5(3).

Add to list

Journal Article
A2
open access

Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults : a phase 2 randomized study

Xavier Saez-Llorens, Claudio Lanata, Elaine Aranguren, Carlos R. Celis, Rubelio Cornejo, Rodrigo DeAntonio, Lucie Ecker, Diegi Garrido, Ana I. Gil, Marina Gonzales, et al.

(2022) VACCINE: X. 11.

Add to list

Journal Article
A1
open access

Harmonization and qualification of intracellular cytokine staining to measure influenza-specific CD4+ T cell immunity within the FLUCOP consortium

Sarah Begue, Gwenn Waerlop (UGent) , Bruno Salaun, Michel Janssens, Duncan Bellamy, Rebecca Jane Cox, Richard Davies, Elena Gianchecchi, Donata Medaglini, Emanuele Montomoli, et al.

(2022) FRONTIERS IN IMMUNOLOGY. 13.

Academic Bibliography

em. prof. dr. Geert Leroux-Roels

Safety and Immunogenicity of a Carbohydrate Fatty Acid Monosulphate Ester Adjuvant Combined with a Low-Dose Quadrivalent Split-Virion Inactivated Influenza Vaccine: A Randomised, Observer-Blind, Active-Controlled, First-in-Human, Phase 1 Study

Safety and immunogenicity of the live-attenuated hRVFV-4s vaccine against Rift Valley fever in healthy adults: a dose-escalation, placebo-controlled, first-in-human, phase 1 randomised clinical trial

Safety and Immunogenicity of a Carbohydrate Fatty Acid Monosulphate Ester Adjuvant Combined with a Low-Dose Quadrivalent Split-Virion Inactivated Influenza Vaccine: A Randomised, Observer-Blind, Active-Controlled, First-in-Human, Phase 1 Study

Immune responses in healthy adults elicited by a bivalent norovirus vaccine candidate composed of GI.4 and GII.4 VLPs without adjuvant

Immunogenicity, safety, and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate : a randomised, double-blind, placebo-controlled, phase 2a trial

Human immunity and susceptibility to influenza A(H3) viruses of avian, equine, and swine origin

Double-blind, placebo-controlled, dose-escalating study evaluating the safety and immunogenicity of an epitope-specific chemically defined nanoparticle RSV vaccine

A human monoclonal antibody against HBsAg for the prevention and treatment of chronic HBV and HDV infection

Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults : a phase 2 randomized study

Harmonization and qualification of intracellular cytokine staining to measure influenza-specific CD4+ T cell immunity within the FLUCOP consortium

Contents

Support

Contact